Shield Therapeutics plc (STX) Ordinary Shares 1.5p
- Add to watchlist
- Create an alert
- This stock can be held in a
n/a
n/a
12.75p
£15.84 million
2.03p
n/a
1.92p
n/a
0.03p (1.25%) Previous:
0.03p
n/a
n/a
15,000
Performance
Not available for this stock.
Fundamental data
Year ending: | 31/12/2022 | 31/12/2021 |
---|---|---|
Revenue (£m) | 4.47 | 1.52 |
Profit before tax (£m) | (40.08) | (19.91) |
Adjusted EPS (p): | (17.00) | (10.00) |
P/E ratio | n/a | n/a |
PEG | n/a | n/a |
EPS growth (%) | n/a | n/a |
Values are quoted in the stock's local currency: British pound
All fundamental dataDividend information for this stock is not available.
Dividend information for this stock is not available.
Ready to invest?
Important Documents
There are no documents available for this stock.
-
Shield Therapeutics reports strong US progress
7 December 2023 13:11
-
Shield's Canadian partner files new drug submission for Accrufer
21 March 2022 11:58
-
Shield Therapeutics revenue falls in line with expectations
17 February 2022 15:51
-
Unaudited Full Year Trading Update
21 February 2024 07:00
-
Appointment of new Chief Financial Officer
9 January 2024 07:00
-
Q3 2023 U.S. Commercial Highlights
7 December 2023 07:00
Recent trade data is unavailable. We will be replacing it, however in the meantime the information is available on the London Stock Exchange website.
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.